Loading
A phase 1/2 trial of Amivantamab, Fluorouracil, FLOT in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05379595 by Janssen Research & Development, LLC, with 225 participants planned, started 2022-07-29 and due to reach its primary completion in 2027-04-27. Interventions recorded: Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan. Conditions listed: Advanced or Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.